BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 25
• 26
• 27
• 28
• 29

• Drug Development

  Protagenic Therapeutics ‘s Neuropeptide Shows Strong Efficacy In Treating Depression And Anxiety Of Established Rodent Models

  September 28, 2017

   · 

  4 min read
• Deals

  Acquisition Of Zevacor Pharma Complete, Rebranding As Sofie

  September 28, 2017

   · 

  6 min read
• BioMidwest

  Spectrum Pharma Highlights Poziotinib Data In Lung Cancer To Be Presented In An Oral Presentation At The 18th IASLC World Conference On Lung Cancer In Yokohama, Japan, October 15- 18, 2017

  September 28, 2017

   · 

  6 min read
• Business

  Insulet Breaks Ground On New U.S. Manufacturing Facility

  September 28, 2017

   · 

  3 min read
• BioMidwest

  NOWDiagnostics’ Whole Blood, Rapid Pregnancy Test Performance Comparable To Standard Lab Tests In UCLA Field Comparison

  September 28, 2017

   · 

  4 min read
• Evotec AG Invests In Exscientia To Advance AI-Driven Drug Discovery

  September 28, 2017

   · 

  6 min read
• FDA

  Regeneron And Sanofi Announce Approval Of DUPIXENT (Dupilumab) To Treat Adult Patients With Moderate-To-Severe Atopic Dermatitis In The European Union

  September 28, 2017

   · 

  14 min read
• Deals

  Fresenius Medical Care Divests Shiel Medical Laboratory to Quest Diagnostics for Undisclosed Sum

  September 28, 2017

   · 

  3 min read
• FDA

  LivaNova And MicroPort Scientific Announce The Approval Of Rega Pacemakers By The China Food And Drug Administration

  September 28, 2017

   · 

  5 min read
• Drug Development

  CBT Pharma Announces First U.S. Patient Dosed In Phase 1 Clinical Trial Of C-Met Inhibitor, CBT-101, For Advanced Solid Tumors With C-Met Dysregulation

  CBT Pharma today announced that the first subject has been dosed in the Phase I multi-center study, CBT-101-01 which is an important milestone for CBT and its employees.

  September 28, 2017

   · 

  3 min read